T8087

Tropolone, a metal chelator, possesses weak antioxidative and radical-scavenging properties and shows a strong affinity for ferric ion

VE-PTP-IN-1 (compound 2) is a selective inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP) with weakly acidic properties, and it plays a role in regulating vascular homeostasis and angiogenesis.

Veligrotug is an intravenously administered anti-insulin-like growth factor-1 receptor antibody developed for the treatment of thyroid eye disease (TED). Veligrotug has demonstrated rapid reductions in diplopia as well as improvements in orbital inflammation, thereby highlighting its potential as a targeted biologic research tool in autoimmune ophthalmopathy.

VEGFR-2-IN-37 (compound 12), a VEGFR-2 inhibitor, demonstrates an inhibition rate of approximately 56.9 μM at 200 μM concentration and is identified as a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation [1].

VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC. It arrests the cell cycle at the S and G2 phases and induces apoptosis in HeLa cells, demonstrating an anti-angiogenic effect [1].

VEGFR-2/c-Met-IN-1 is a dual inhibitor of VEGFR-2 and c-Met, with IC50 values of 138 nM and 74 nM, respectively, demonstrating antitumor activity [1].

Vatelizumab is a humanised monoclonal antibody targeting Integrin α2β1 (very late antigen 2, VLA-2, CD49b), which enhances the frequency of regulatory T cells via the p38 MAPK signalling pathway and can be used for research into multiple sclerosis.

Vasomera, a stable, long-acting vasoactive intestinal peptide (VIP) agonist, targets G-protein-coupled VPAC2 receptors and is employed in the study of cardiomyopathy associated with dystrophinopathies [1].

Varisacumab (R 84) is a sophisticated human recombinant monoclonal antibody target Vascular Endothelial Growth Factor A (VEGFA), thereby effectively neutralizing its interaction with both VEGFR1 and VEGFR2 receptors. Varisacumab (R 84) has demonstrated anti-angiogenic properties in preclinical models and is extensively utilized for research involving malignancy and microvascular complications of diabetes.

Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate used in Alzheimer's disease (AD) research [1].

Vamagloxistat is a glycolate oxidase inhibitor utilized to mitigate hyperoxaluria and reduce the formation of kidney stones [1].